1,2,4]三唑并[4,3-A]吡啶-8-醇 | 1065608-72-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 中文名称: 1,2,4]三唑并[4,3-A]吡啶-8-醇
• 英文名称: [1,2,4]triazolo[4,3-a]pyridin-8-ol
• CAS: 1065608-72-1
• 化学式: C₆H₅N₃O
• 分子量: 135.125
• InChiKey: NLKMQTGBGLPINQ-UHFFFAOYSA-N

物化性质

• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,2,4]三唑并[4,3-A]吡啶-8-醇 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 生成 4,5,6,7-四氢-2,1,3-苯并噁二唑-4-酮
  参考文献：
  名称：

  Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors

  摘要：

  A class of imidazoisoindole (III) heme-binding indoleamine-2,3-dioxygenase (IDO1) inhibitors were optimized via structure-based drug design into a series of tryptophan-2,3-dioxygenase (TDO)-selective inhibitors. Kynurenine pathway modulation was demonstrated in vivo, which enabled evaluation of TDO as a potential cancer immunotherapy target. As means of mitigating the risk of drug-drug interactions arising from cytochrome P450 inhibition, a novel property-based drug design parameter, herein referred to as the CYP Index, was implemented for the design of inhibitors with appreciable selectivity for TDO over CYP3A4. We anticipate the CYP Index will be a valuable design parameter for optimizing CYP inhibition of any small molecule inhibitor containing a Lewis basic motif capable of binding heme.

  DOI：

  10.1021/acsmedchemlett.0c00004
• 作为产物：
  描述：

  3-benzyloxy 2-chloropyridine 在 palladium on activated charcoal 、 氢气 、 potassium carbonate 、 肼 作用下， 以 甲醇 、 异丙醇 为溶剂， 25.0~160.0 ℃ 、101.33 kPa 条件下， 生成 1,2,4]三唑并[4,3-A]吡啶-8-醇
  参考文献：
  名称：

  Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors

  摘要：

  A class of imidazoisoindole (III) heme-binding indoleamine-2,3-dioxygenase (IDO1) inhibitors were optimized via structure-based drug design into a series of tryptophan-2,3-dioxygenase (TDO)-selective inhibitors. Kynurenine pathway modulation was demonstrated in vivo, which enabled evaluation of TDO as a potential cancer immunotherapy target. As means of mitigating the risk of drug-drug interactions arising from cytochrome P450 inhibition, a novel property-based drug design parameter, herein referred to as the CYP Index, was implemented for the design of inhibitors with appreciable selectivity for TDO over CYP3A4. We anticipate the CYP Index will be a valuable design parameter for optimizing CYP inhibition of any small molecule inhibitor containing a Lewis basic motif capable of binding heme.

  DOI：

  10.1021/acsmedchemlett.0c00004

文献信息

• 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS
  申请人：Aicher Thomas Daniel

  公开号：US20100105659A1

  公开（公告）日：2010-04-29

  Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了一些化合物，这些化合物在治疗和/或预防由葡萄糖激酶活性不足引起的疾病中非常有用，例如糖尿病。同时提供了治疗或预防由葡萄糖激酶活性不足或可以通过激活葡萄糖激酶治疗的疾病和疾病的方法。
• 2-aminopyridine analogs as glucokinase activators
  申请人：Aicher Thomas Daniel

  公开号：US08362037B2

  公开（公告）日：2013-01-29

  Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了一些化合物，这些化合物在治疗和/或预防由葡萄糖激酶活性不足引起的疾病（如糖尿病）方面非常有用。同时还提供了治疗或预防由葡萄糖激酶活性不足或可以通过激活葡萄糖激酶来治疗的疾病和疾病的方法。
• WO2008/118718
  申请人：——

  公开号：——

  公开（公告）日：——
• US8362037B2
  申请人：——

  公开号：US8362037B2

  公开（公告）日：2013-01-29
• [EN] 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS<br/>[FR] ANALOGUES DE LA 2-AMINOPYRIDINE COMME ACTIVATEURS DE LA GLUCOKINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2008118718A2

  公开（公告）日：2008-10-02

  [EN] Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
  [FR] La présente invention concerne des composés qui sont utiles dans le traitement et/ou la prévention de maladies provoquées par des niveaux déficients de l'activité de la glucokinase, telles que le diabète sucré. L'invention concerne également des procédés de traitement ou de prévention de maladies et de troubles caractérisés par une sous-activité de la glucokinase ou qui peuvent être traités en activant la glucokinase.